Search
01/01/2023
Sensitization to isothiazolinones in the Spanish Contact Dermatitis Registry (REIDAC): 2019–2021 epidemiological situation
Hernández Fernández C.P., Borrego L., Mercader García P., Giménez Arnau A.M., Sánchez Pérez J., Silvestre Salvador J.F., González Pérez R., Sanz Sánchez T., Sánchez Gilo A., Melé Ninot G., Zaragoza Ninet V., Miquel Miquel F.J., Carrascosa Carrillo J.M., Córdoba Guijarro S., Gatica Ortega M.E., Ruiz González I., Serra Baldrich E., Tous Romero F., Rodríguez Serna M., Pastor Nieto M.A., Pérez Feal P., Hervella Garcés M., de Vega Martínez M., García Doval I.. Sensitization to isothiazolinones in the Spanish Contact Dermatitis Registry (REIDAC): 2019–2021 epidemiological situation. CONTACT DERMATITIS. 2023; 88(3)DOI:10.1111/cod.14251. PMID:36403138. IF:4.800(Q1/2D).
01/01/2023
Development and validation of a minimally invasive and image-guided tape stripping method to sample atopic skin in children
Yélamos O., Andersen D., Pont M., Iglesias P., Potrony M., Domínguez M., Herrero A., Alejo B., Mateu J., Røpke M., Danneskiold-Samsøe N.B., Malvehy J., Guy R.H., Brix S., Puig S.. Development and validation of a minimally invasive and image-guided tape stripping method to sample atopic skin in children. CLINICAL AND EXPERIMENTAL DERMATOLOGY. 2023; 48(2)DOI:10.1093/ced/llac040. PMID:36730521. IF:3.700(Q1/2D).
01/01/2023
Psoriasis treatment does not impair the immunogenicity of ChAOx1-S[recombinant] COVID-19 vaccination
Puig L.. Psoriasis treatment does not impair the immunogenicity of ChAOx1-S[recombinant] COVID-19 vaccination. BRITISH JOURNAL OF DERMATOLOGY. 2023; 188(2)DOI:10.1093/bjd/ljac081. PMID:36763894. IF:11.000(Q1/1D).
01/01/2023
Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes
Egeberg A., Merola J.F., Schäkel K., Puig L., Mahar P.D., Wang I.Y., Pavo I., Schuster C., Griffiths C.E.M.. Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes. Frontiers in Medicine. 2023; 9DOI:10.3389/fmed.2022.1092688. PMID:36777159. IF:3.100(Q1/2D).
01/01/2023
The social value of a PASI 90 or PASI 100 response in patients with moderate-to-severe plaque psoriasis in Spain
Maravilla-Herrera P., Merino M., Alfonso Zamora S., Balea Filgueiras J., Carrascosa Carrillo J.M., Delgado Sánchez O., Dolz Sinisterra F., García-Ruiz A., Herranz Pinto P., Manfredi A., Martínez Olmos J., Morales de los Ríos Luna P., Puig L., Ros S., Hidalgo-Vega Á.. The social value of a PASI 90 or PASI 100 response in patients with moderate-to-severe plaque psoriasis in Spain. Frontiers in Public Health. 2023; 11DOI:10.3389/fpubh.2023.1000776. PMID:36778548. IF:3.000(Q2/3D).
01/01/2023
The impact of achieving and maintaining near-complete or complete skin clearance on patient quality of life in moderate-to-severe psoriasis
Ryan C., Puig L., Zema C., Thompson E.H.Z., Yang M., Wu E., Bensimon A., Huang X., Joshi A.D., Elewski B.. The impact of achieving and maintaining near-complete or complete skin clearance on patient quality of life in moderate-to-severe psoriasis. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2023; 88(1)DOI:10.1016/j.jaad.2021.12.032. PMID:34954285. IF:12.800(Q1/1D).